A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Pharmacometabolomics may decrease the burden on the healthcare system by better gauging the correct choice of treatment drug and dosage in order to optimize the response of a patient to a treatment. Hopefully, this approach will also ultimately limit the number of adverse drug reactions (ADRs) associated with many treatment regimens. Overall, physicians would be better able to apply more personalized, and potentially more effective, treatments to their patients. It is important to consider, however, that the processing and analysis of the patient samples takes time, resulting in delayed treatment. Another concern about the application of pharmacometabolomics analyses to individual patient care, is deciding who should and who should not receive this in-depth, personalized treatment protocol. Certain diseases and stages of disease would have to be classified according to their requirement of such a treatment plan, but there are no criteria for this classification. Furthermore, not all hospitals and treatment institutes can afford the equipment to process and analyze patient samples on site, but sending out samples takes time and ultimately delays treatment. Health insurance coverage of such procedures may also be an issue. Certain insurance companies may discriminate against the application of this type of sample analysis and metabolite characterization. Furthermore, there would have to be regulations put in place to ensure that there was no discrimination by insurance companies against the metabolic profiles of individual patients ("high metabolizers" vs.
Dhamara Fishing Harbour is an international standard Harbour. The Harbour is located in the North Bank of Dhamra River in the revenue village Dhamara, Dist. Bhadrak. It has become the first harbour certified by Export Inspection Agency (EIA) in the state following approval of the Export Inspection Council (EIC), India and meets the Euro standard fish food as specified by European Union. The major species landing in the jetties are (i) Pomfret (ii) Shrimps (iii) Bombay Duck (iv) Hilsha (v) Mackerel (vi) Johnius (Vii) Ribbon fish (Viii) Megalops (ix) Borei etc. These species have high demand both in National and International market. All these fish landings are maintained with proper cold chain and processed hygienically for value addition to fetch good price in the market which are regularly checked by the Harbour Authorities for maintenance of the quality.
=== Drew Holt === Andrew "Drew" Holt (Miles Heizer) is Sarah's son, age 14 at the beginning of the series. He is characterized as sensitive and longs for a male role model. Brief glimpses of Seth (Drew's absentee father) and statements by Sarah indicate that Drew has suffered much disappointment at the hands of his dad. As a result, he has become sullen and withdrawn. Drew regularly seeks romantic advice from the male figures in his life, Zeek and Adam. Drew plays baseball in the first two seasons, with Adam's help, and shows Max how to catch a fly ball. During the third season, Drew develops a relationship with Amy, a girl introduced to him by his grandfather during a yard sale. The relationship with his new girlfriend, Amy, helps him to become less aloof and break the shell of his social inhibitions. He is shown having trouble adjusting to his mother's relationship with Mark Cyr, a teacher at his high school. In the season three finale, Drew and Amy sleep together for the first time, while his family celebrates Crosby and Jasmine's wedding outside. During the beginning of the fourth season, Amy breaks up with Drew after meeting someone else over the summer. They try to stay friends, but later get back together after Amy learns of his aunt's cancer. They are caught having sex by Mark, who tells Drew's mother. Amy eventually ends up pregnant. She, however, has an abortion and decides it is best for her to stay single. At the end of season four, Drew is accepted into the University of California, Berkeley.
==== Dercum's disease ==== Lipedema / Dercum's disease differentiation – these conditions may co-exist. Dercum's disease is a syndrome of painful growths in subcutaneous fat. Unlike lipedema, which occurs primarily in the trunk and legs, the fatty growths can occur anywhere on the body.
Sources: en.wikipedia.org
== Personal life == Sherman met and married Hildegard Schroeder while they were both graduate students at the University of Iowa, and they had three children: Karen, Marc, and Keith. In addition to his professional activities, he has participated in organizations such as the Boy Scouts of America, the Jewish War Veterans organization, and the Lions Club. Sherman died on December 1, 2023, at the age of 98.
=== Molecular mechanism === At the molecular level, a cell senses insulin through insulin receptors, with the signal propagating through the insulin signal transduction pathway. Recent studies suggested that the pathway may operate as a bistable switch under physiologic conditions for certain types of cells, and insulin response may well be a threshold phenomenon. The pathway's sensitivity to insulin may be blunted by many factors such as lipolysis of free fatty acids, causing insulin resistance. From a broader perspective, however, sensitivity tuning (including sensitivity reduction) is a common practice for an organism to adapt to the changing environment or metabolic conditions. Pregnancy, for example, entails significant metabolic changes, during which the mother must decrease the insulin sensitivity of her muscles to conserve more glucose for both the maternal and fetal brains. This adaptation can occur by elevating the response threshold, thereby delaying the onset of sensitivity. This is achieved through the secretion of placental growth factor, which interferes with the interaction between insulin receptor substrate (IRS) and PI3K. This concept forms the basis of the adjustable threshold hypothesis of insulin resistance. Insulin resistance has been proposed to be a reaction to excess nutrition by superoxide dismutase in cell mitochondria that acts as an antioxidant defense mechanism. This link seems to exist under diverse causes of insulin resistance.
The biosynthesis of melatonin in animals involves a sequence of enzymatic reactions starting with L-tryptophan, which can be synthesized through the shikimate pathway from chorismate, found in plants, or obtained from protein catabolism. The initial step in the melatonin biosynthesis pathway is the hydroxylation of L-tryptophan's indole ring by the enzyme tryptophan hydroxylase, resulting in the formation of 5-hydroxytryptophan (5-HTP). Subsequently, 5-HTP undergoes decarboxylation, facilitated by pyridoxal phosphate and the enzyme 5-hydroxytryptophan decarboxylase, yielding serotonin. Serotonin, an essential neurotransmitter, is further converted into N-acetylserotonin by the action of serotonin N-acetyltransferase, using acetyl-CoA. The final step in the pathway involves the methylation of N-acetylserotonin's hydroxyl group by hydroxyindole O-methyltransferase, with S-adenosyl methionine as the methyl donor, to produce melatonin. In bacteria, protists, fungi, and plants, the synthesis of melatonin also involves tryptophan as an intermediate but originates indirectly from the shikimate pathway. The pathway commences with D-erythrose 4-phosphate and phosphoenolpyruvate, and in photosynthetic cells, additionally involves carbon dioxide. While the subsequent biosynthetic reactions share similarities with those in animals, there are slight variations in the enzymes involved in the final stages.
Bupropion is more effective than selective serotonin reuptake inhibitors (SSRIs) at improving symptoms of hypersomnia and fatigue in depressed patients. Bupropion is effective in the treatment of depression with comorbid anxiety (also known as anxious depression) and, contrary to common belief, does not exacerbate anxiety in this context. The effectiveness of bupropion for anxious depression is equivalent to that of SSRIs in the case of depression with low or moderate anxiety, whereas SSRIs show a modest effectiveness advantage in terms of response rates for depression with high anxiety. In contrast to other antidepressants like SSRIs, bupropion is not approved for treatment of anxiety disorders. The addition of bupropion to a prescribed SSRI is a common strategy when people do not respond to the SSRI, and it is supported by clinical trials. However, it appears to be inferior to the addition of atypical antipsychotic aripiprazole.
Thus, the two substrates of this enzyme are isopregnanolone and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 5α-dihydroprogesterone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3β-hydroxy-5α-steroid:NADP+ 3-oxidoreductase.
Sources: en.wikipedia.org
I must tell you that I can make urea without the use of kidneys, either man or dog. Ammonium cyanate is urea. His second sentence was incorrect. Ammonium cyanate [NH4]+[OCN]− and urea CO(NH2)2 are two different chemicals with the same empirical formula CON2H4, which are in chemical equilibrium heavily favoring urea under standard conditions.
=== Physical effects === Common responses include pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions). Psilocybin's sympathomimetic or cardiovascular effects, including increased heart rate and blood pressure, are usually mild. On average, peak heart rate is increased by 5 bpm, peak systolic blood pressure by 10 to 15 mm Hg, and peak diastolic blood pressure by 5 to 10 mm Hg. But temporary increases in blood pressure can be a risk factor for users with preexisting hypertension. Psilocybin's somatic effects have been corroborated by several early clinical studies. A 2005 magazine survey of clubgoers in the UK found that over a quarter of those who had used psilocybin mushrooms in the preceding year experienced nausea or vomiting, although this was caused by the mushroom rather than psilocybin itself. In one study, administration of gradually increasing doses of psilocybin daily for 21 days had no measurable effect on electrolyte levels, blood sugar levels, or liver toxicity tests.
=== Research === Sherrill develops methods, algorithms, and software for quantum chemistry. He has introduced efficient density-fitting techniques into several quantum chemistry methods, speeding up computations. His research group obtains highly-accurate results for important prototype chemical systems, and uses these results to develop computational protocols that are faster yet still accurate. Sherrill focuses on intermolecular interactions, and has published definitive studies of the strength, geometric dependence, and substituent effects in prototype interactions including π-π, CH/π, S/π, and cation-π interactions. He has developed extensions of symmetry-adapted perturbation theory (SAPT) to analyze these interactions in terms of their fundamental physical forces (electrostatics, exchange/steric repulsion, induction/polarization, and London dispersion forces). A fragment-based partitioning of SAPT allows analyses of which non-bonded contacts are most important for binding, and has been used to understand substituent effects in protein-drug binding. Sherrill has published over 200 peer-reviewed articles on these topics, and presented over 130 invited lectures, including the 2011 Robert S. Mulliken Lecture at the University of Georgia, the keynote talk for the 2015 Workshop on Control of London Dispersion Interactions in Molecular Chemistry in Göttingen, and keynote talks at the 2015 and 2016 meetings of the Southeast Theoretical Chemistry Association.
{\displaystyle {\boldsymbol {\sigma }}=-\left[p-\left(\lambda +{\tfrac {2}{3}}\mu \right)\left(\nabla \cdot \mathbf {u} \right)\right]\mathbf {I} +\mu \left(\nabla \mathbf {u} +\left(\nabla \mathbf {u} \right)^{\mathsf {T}}-{\tfrac {2}{3}}\left(\nabla \cdot \mathbf {u} \right)\mathbf {I} \right)}
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.